Suppr超能文献

相似文献

1
Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis.
Gastroenterology. 2022 Jul;163(1):163-173. doi: 10.1053/j.gastro.2022.03.037. Epub 2022 Mar 29.
2
Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.
Clin Gastroenterol Hepatol. 2017 Sep;15(9):1397-1404.e7. doi: 10.1016/j.cgh.2017.02.017. Epub 2017 Feb 24.
3
Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.
Ann Intern Med. 2003 Feb 4;138(3):176-86. doi: 10.7326/0003-4819-138-3-200302040-00009.
4
Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
Ann Surg. 2004 Jun;239(6):849-56; discussion 856-8. doi: 10.1097/01.sla.0000128303.05898.ee.
5
Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies.
Am J Gastroenterol. 2011 Feb;106(2):254-60. doi: 10.1038/ajg.2010.470. Epub 2010 Dec 7.
6
Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening.
Am J Gastroenterol. 2021 Aug 1;116(8):1620-1631. doi: 10.14309/ajg.0000000000001336.
7
Barrett's Esophagus Risk Factors in Patients Without Gastroesophageal Reflux: A Large Population-Based Study.
Clin Gastroenterol Hepatol. 2024 Oct;22(10):2150-2152.e2. doi: 10.1016/j.cgh.2024.03.034. Epub 2024 Apr 24.
8
Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review.
JAMA. 2002 Apr 17;287(15):1972-81. doi: 10.1001/jama.287.15.1972.
10
Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2024 Jul;22(7):1381-1394.e7. doi: 10.1016/j.cgh.2023.10.006. Epub 2023 Oct 24.

引用本文的文献

1
Cost effectiveness analysis of Barrett's esophagus screening: A systematic review.
Best Pract Res Clin Gastroenterol. 2025 Mar;75:101980. doi: 10.1016/j.bpg.2025.101980. Epub 2025 Jan 9.
3
Esophageal cancer screening, early detection and treatment: Current insights and future directions.
World J Gastrointest Oncol. 2024 Apr 15;16(4):1180-1191. doi: 10.4251/wjgo.v16.i4.1180.
4
The Public's Intended Uptake of Hypothetical Esophageal Adenocarcinoma Screening Scenarios: A Nationwide Survey.
Am J Gastroenterol. 2024 Sep 1;119(9):1802-1812. doi: 10.14309/ajg.0000000000002812. Epub 2024 Apr 15.
5
Missed Opportunities: the Timing and Frequency of Screening Colonoscopy in Patients That Develop Esophageal Adenocarcinoma.
J Gastrointest Surg. 2023 Dec;27(12):2711-2717. doi: 10.1007/s11605-023-05874-8. Epub 2023 Nov 6.
6
New Techniques to Screen for Barrett Esophagus.
Gastroenterol Hepatol (N Y). 2023 Jul;19(7):383-390.
7
Prevalence and Predictors of Barrett's Esophagus After Negative Initial Endoscopy: Analysis From Two National Databases.
Clin Gastroenterol Hepatol. 2024 Mar;22(3):523-531.e3. doi: 10.1016/j.cgh.2023.08.035. Epub 2023 Sep 15.
8
Dutch individuals' views of screening for oesophageal cancer: a focus group study.
BMJ Open Gastroenterol. 2023 May;10(1). doi: 10.1136/bmjgast-2023-001136.
9
Expression and significance of CDX2, FXR, and TGR5 in esophageal cancer.
Int J Clin Exp Pathol. 2022 Sep 15;15(9):354-363. eCollection 2022.

本文引用的文献

1
Race-Based Clinical Recommendations in Gastroenterology.
Gastroenterology. 2022 Feb;162(2):408-414.e2. doi: 10.1053/j.gastro.2021.12.234. Epub 2021 Dec 7.
2
Population Attributable Risks of Subtypes of Esophageal and Gastric Cancers in the United States.
Am J Gastroenterol. 2021 Sep 1;116(9):1844-1852. doi: 10.14309/ajg.0000000000001355.
3
Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening.
Am J Gastroenterol. 2021 Aug 1;116(8):1620-1631. doi: 10.14309/ajg.0000000000001336.
5
Cost-Effectiveness of Screening, Surveillance, and Endoscopic Eradication Therapies for Managing the Burden of Esophageal Adenocarcinoma.
Gastrointest Endosc Clin N Am. 2021 Jan;31(1):77-90. doi: 10.1016/j.giec.2020.08.005. Epub 2020 Oct 26.
6
Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling.
Clin Gastroenterol Hepatol. 2020 Aug;18(9):1961-1969. doi: 10.1016/j.cgh.2019.11.058. Epub 2019 Dec 6.
7
Circulating Sex Hormone Levels and Risk of Esophageal Adenocarcinoma in a Prospective Study in Men.
Am J Gastroenterol. 2020 Feb;115(2):216-223. doi: 10.14309/ajg.0000000000000446.
8
ASGE guideline on screening and surveillance of Barrett's esophagus.
Gastrointest Endosc. 2019 Sep;90(3):335-359.e2. doi: 10.1016/j.gie.2019.05.012.
9
Constitutively Higher Level of GSTT2 in Esophageal Tissues From African Americans Protects Cells Against DNA Damage.
Gastroenterology. 2019 Apr;156(5):1404-1415. doi: 10.1053/j.gastro.2018.12.004. Epub 2018 Dec 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验